Results 211 to 220 of about 114,562 (319)

Urine‐Based Bladder Cancer Diagnostics: A Local Evaluation of Cxbladder and Review of the ANZ Landscape

Trends in Urology &Men's Health, Volume 17, Issue 2, April 2026.
ABSTRACT The high demand for cystoscopies performed for bladder cancer diagnosis or surveillance imposes a significant burden on regional centres with limited capacity. Cxbladder is a urinary biomarker test that estimates the likelihood of bladder cancer.
Claris Oh, Kim Tien Chah, Kian Lotter, Steven Lun, Manuel Yuhico   +4 more
wiley   +1 more source

FGFR Testing in Metastatic Urothelial Carcinoma-Who, When, and How to Test. [PDF]

Cancers (Basel)
Mansinho A, Machado JC, Faustino C, Figueiredo A, Moreira Pinto J, Vau N, Ramalho-Carvalho J, Teixeira MR.   +7 more
europepmc   +1 more source

Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis

, 2019
Xuansheng Ding, Qian Chen, Zhen Yang, Li J, Haocheng Zhan, Nianli Lu, Mark Chen, Yunpeng Yang, Jiguang Wang, Dong‐Hua Yang   +9 more
openalex   +1 more source

Cutaneous Immune‐Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ Malignancies

International Journal of Dermatology, Volume 65, Issue 4, Page 790-796, April 2026.
ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced solid tumors. While low‐grade immune‐related adverse events (irAEs) are associated with prolonged survival, high‐grade irAEs have been associated with poorer survival. Cutaneous immune‐related adverse events (cirAEs) affect up to 20%
David O'Reilly, Gregg Murray, Orla M Fitzpatrick, Hebatalla Ismail, Gavin P Dowling, Gargi Roy, David Synnott, Maggie O'Connor, Bryan T Hennessy, Oscar Breathnach, Liam Grogan, Megan Greally, Adrian Murphy, Patrick G Morris, Karen Eustace, Muireann Roche, Stephen Madden, Jarushka Naidoo   +17 more
wiley   +1 more source

Predictors of Response and Mechanisms of Resistance to Antibody Drug Conjugates in Urothelial Carcinoma. [PDF]

Curr Oncol
Huang J, Ojo A, Liaw B.
europepmc   +1 more source

Interstitial lung disease induced by Toripalimab combined with disitamab Vedotin in upper tract urothelial carcinoma: a case report and literature review [PDF]

Peng Ding, Hang Lin, Kaichen Zhang, Qian Yang, Peiyang Gao   +4 more
openalex   +1 more source

Establishment of a canine urothelial carcinoma‐derived organoid biobank: A platform for comparative and translational research

Clinical and Translational Medicine, Volume 16, Issue 4, April 2026.
Christopher Zdyrski, Aleksandra Pawlak, Hannah F. Nicholson, Megan P. Corbett, Michael Catucci, John Cheville, Haejin Cho, Bryan J. Melvin, Jiayi Peng, Corey Saba, Hayden Hamsher, Steven G. Friedenberg, Andrew P. Woodward, Eugene Douglass, Jonathan P. Mochel, Karin Allenspach   +15 more
wiley   +1 more source

Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis

International Journal of Cancer, Volume 158, Issue 6, Page 1654-1665, 15 March 2026.
What's new? New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.
Dora Niedersuess‐Beke, Karl Mayrhofer, Johanna Krauter, Johannes Franke, Dominic Vais, Maximillian Pallauf, David Kiesl, Ferdinand Luger, Jacob Pfuner, Angelika Terbuch, Thomas Bauernhofer, Jasmin Spielgelberg, Andreas Banner, Stefan Aufderklamm, Clemens Wiesinger, Susanne Schnabel, Simon Peter Gampenrieder, Josef Mühlmann, Sonia Vallet, Sabine Weibrecht, Franz Stoiber, Haleh Andalibi, Harun Fajkovic, Hossein Taghizadeh, Jan Miechowiecki, Roman Taedcke, Daniel Heintel, Shahrokh F. Shariat, Martin Pichler, Wolfgang Hilbe, Renate Pichler   +30 more
wiley   +1 more source

First reported case of peri-ureteric urothelial carcinoma. [PDF]

Urol Case Rep
Gholami M, Lam J.
europepmc   +1 more source

Current Landscape and Evolving Role of Targeted Agents in Urothelial Carcinoma. [PDF]

Cancers (Basel)
Sammarco E, Pellino A, Bona E, Farnesi A, Biasco E, Caparello C, Marini A, Stasi I, Musettini G, Barbara C, De Maio E, Coltelli L, Cupini S, Allegrini G.   +13 more
europepmc   +1 more source